La réémergence de la coqueluche en Tunisie

Zouari, Asma; Smaoui, H.; Njamkepo, Elisabeth; Mnif, Khaled; Jaballah, N. Ben; Bousnina, S.; Barsaoui, Sihem; Sammoud, A.; Bêcher, S. Ben; Guiso, Nicole; Kechrid, A.

doi:10.1016/j.medmal.2010.11.008

Cited by 9 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, young infants are at highest risk for severe outcomes, such as respiratory failure and death (189,191,278,280,290,(293)(294)(295)(296)(297)(298)(299)(300)(301)(302)(303)(304)(305)(306)(307)(308)(309)(310)(311). In the United States, it has been estimated that more than half of infants infected with pertussis require hospitalization, and about one in 100 infants die as a result of pertussis (272,312).…”

Section: Complications Of Pertussis In Infants Children and Adultsmentioning

confidence: 99%

Pertussis: Microbiology, Disease, Treatment, and Prevention

et al. 2016

View full text Add to dashboard Cite

SUMMARYPertussis is a severe respiratory infection caused byBordetella pertussis, and in 2008, pertussis was associated with an estimated 16 million cases and 195,000 deaths globally. Sizeable outbreaks of pertussis have been reported over the past 5 years, and disease reemergence has been the focus of international attention to develop a deeper understanding of pathogen virulence and genetic evolution ofB. pertussisstrains. During the past 20 years, the scientific community has recognized pertussis among adults as well as infants and children. Increased recognition that older children and adolescents are at risk for disease and may transmitB. pertussisto younger siblings has underscored the need to better understand the role of innate, humoral, and cell-mediated immunity, including the role of waning immunity. Although recognition of adult pertussis has increased in tandem with a better understanding ofB. pertussispathogenesis, pertussis in neonates and adults can manifest with atypical clinical presentations. Such disease patterns make pertussis recognition difficult and lead to delays in treatment. Ongoing research using newer tools for molecular analysis holds promise for improved understanding of pertussis epidemiology, bacterial pathogenesis, bioinformatics, and immunology. Together, these advances provide a foundation for the development of new-generation diagnostics, therapeutics, and vaccines.

show abstract

Section: Complications Of Pertussis In Infants Children and Adultsmentioning

confidence: 99%

Pertussis: Microbiology, Disease, Treatment, and Prevention

et al. 2016

View full text Add to dashboard Cite

show abstract

“…However, a study performed at the Children's Hospital of Tunis using real-time PCR confirms that these numbers are an underestimate. 20,23 In this study, nasopharyngeal aspirates (n = 360) were taken from 350 patients with suspected pertussis between March 2007 and February 2010. Real-time PCR results were positive in 36% of cases even though cultures were negative for all specimens.…”

Section: Pertussis Vaccination By Regionmentioning

confidence: 99%

The Global Pertussis Initiative: Meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010

Guiso¹,

Liese²,

Plotkin³

2011

Human Vaccines

View full text Add to dashboard Cite

Despite the widespread availability of 2 classes of effective vaccines, whole cell and acellular, Bordetella pertussis infection remains a global epidemic. Pertussis is primarily a disease of childhood; however, in countries with high vaccine coverage in children, the distribution of cases appears to have shifted to adolescents and adults. The waning of vaccine-induced and naturally acquired immunity underlie these observations. The Global Pertussis Initiative (GPI) is an expert forum that aims to raise awareness about pertussis and to recommend effective vaccination strategies for disease control. This paper reports the proceedings of the Fourth GPI Regional Roundtable Meeting held in France in April 2010, which involved representatives from 21 countries in Central and Eastern Europe, the Middle East and Africa. A 3-dose primary immunization series with a booster dose in the second year is recommended in nearly every country from these regions. Preschool booster doses are also widely recommended in Central and Eastern Europe and the Middle East. Adolescent vaccination has been implemented in the Czech Republic and Hungary. Epidemiological data indicate that adolescent vaccination would be beneficial in several other Central and Eastern European countries but premature in other regions. The cocoon strategy (selective immunization of mothers, family and close contacts of neonates) has not yet been introduced in any country, although the Czech Republic is considering introducing it. There is widespread support for the vaccination of healthcare workers involved with children, although implementation is likely to require educational initiatives and support from employers. In all regions, surveillance systems for pertussis are generally passive and the disease is probably underreported. Adequate diagnostic facilities are lacking in several countries. Improved surveillance and detection will permit a more accurate assessment of the epidemiology of pertussis and the need for vaccination after childhood.

show abstract

“…Although pertussis vaccination has widely reduced the morbidity and mortality due to whooping cough, an 'apparent' re-emergence of this disease has been experienced worldwide in the last two decades (Munoz, 2006;Cherry, 2010;Zouari et al, 2011). Several reasons for this resurgence have been proposed, including genetic changes in Bordetella pertussis, lessened potency of pertussis vaccines, waning of vaccine-induced immunity, greater awareness of pertussis, and the general availability of better laboratory tests (He & Mertsola, 2008).…”

Section: Introductionmentioning

confidence: 99%

“…In Tunisia, pertussis is a statutory notifiable disease and notification is exclusively based on clinical criteria. Vaccine coverage in Tunisian infants is very high: it accounted for 98 % in 2009 (Zouari et al, 2011). The Tunisian vaccine schedule comprises a primary immunization with three doses of the whole-cell pertussis vaccine administered at the age of 2, 3 and 6 months.…”

Section: Introductionmentioning

confidence: 99%

“…A booster dose is recommended at 18 months of age (http://www.santetunisie.rns.tn/msp/ presentation/vaccination.html). Infants too young to be completely vaccinated account for the majority of pertussis-related complications, hospitalizations and deaths (de Greeff et al, 2010;Zouari et al, 2011). To protect infants against pertussis, the main sources of the infection must be identified.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation